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We studied here the independent roles of angiotensin II and
aldosterone in regulating the sodium chloride cotransporter
(NCC) of the distal convoluted tubule. We adrenalectomized
three experimental and one control group of rats. Following
surgery, the experimental groups were treated with either a
high physiological dose of aldosterone, a non-pressor, or a
pressor dose of angiotensin II for 8 days. Aldosterone and
both doses of angiotensin II lowered sodium excretion and
significantly increased the abundance of NCC in the plasma
membrane compared with the control. Only the pressor dose
of angiotensin II caused hypertension. Thiazides inhibited the
sodium retention induced by the angiotensin II non-pressor
dose. Both aldosterone and the non-pressor dose of
angiotensin II significantly increased phosphorylation of NCC
at threonine-53 and also increased the intracellular
abundance of STE20/SPS1-related, proline alanine-rich kinase
(SPAK). No differences were found in other modulators of
NCC activity such as oxidative stress responsive protein type
1 or with-no-lysine kinase 4. Thus, our in vivo study shows
that aldosterone and angiotensin II independently increase
the abundance and phosphorylation of NCC in the setting of
adrenalectomy; effects are likely mediated by SPAK. These
results may explain, in part, the hormonal control of renal
sodium excretion and the pathophysiology of several forms
of hypertension.
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The conservation of sodium by the kidney is crucial for
maintaining the extracellular fluid volume. The signal for the
kidneys to conserve sodium is largely mediated by the
renin–angiotensin–aldosterone system. Indeed, the majority
of the renal sodium transporters were found to be regulated
by this system, including the sodium hydrogen exchanger
type 3 by angiotensin II,1 and both the sodium chloride
cotransporter (NCC) and the epithelial sodium channel
(ENaC) by aldosterone.2,3 In recent years, a number of
interacting kinase systems have been identified in the distal
nephron, which directly or indirectly regulates renal sodium
transport. The with-no-lysine kinases (WNK) positively or
negatively regulate NCC and ENaC.4–6 STE20/SPS1-related,
proline alanine-rich kinase (SPAK) and oxidative stress
responsive protein type 1 (OSR1) have been identified as
proteins that are capable of phosphorylating NCC.7,8 Finally,
serum- and glucocorticoid-inducible kinase 1 (SGK1) is
pivotal in the regulation of ENaC,9 and probably also
NCC.10,11 These kinases were found to be sensitive to
angiotensin II and aldosterone, which suggested them to
have a central position in the receptor–transporter cas-
cade.4,9,12,13 However, one crucial and unresolved question
remains: what is the independent role of each of these
hormones on sodium regulation in the distal nephron?14,15
We hypothesize that angiotensin II has effects independent of
aldosterone on the renal sodium transporters and their
regulatory kinases in the distal nephron. To test this, we
conducted an experiment in which normal rats underwent
adrenalectomy and then received either angiotensin II
or aldosterone. Our results demonstrate specific effects
of angiotensin II on the abundance and phosphorylation of
NCC and its regulatory kinases.
RESULTS
Renin–angiotensin–aldosterone system
The experimental set-up is shown in Table 1. Briefly, to
analyze the independent effects of angiotensin II, all groups
first underwent adrenalectomy and then received vehicle
(control group), aldosterone (Aldo group, 50 mg/kg/day), or
angiotensin II in a non-pressor (233 mg/kg/day) or a pressor
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(700 mg/kg/day) dose for 8 days.16,17 A fifth group of sham-
operated rats was used only as a normal reference for plasma
renin activity, and plasma angiotensin I, II, and aldosterone
concentrations. As expected, plasma renin activity was
reduced in the angiotensin II-treated groups compared with
control (Figure 1a). Plasma renin activity was also reduced in
the aldosterone-treated group, but only compared with the
sham-operated animals. Plasma angiotensin I, but not
plasma angiotensin II, followed the changes in plasma renin
activity (Figure 1b and c). Plasma aldosterone showed high
physiological levels in the aldosterone-treated group, normal
levels in the sham-operated controls, and virtually undetect-
able levels in the other adrenalectomized groups (Figure 1d).
Effects of aldosterone and angiotensin II on blood pressure,
renal function, and sodium excretion
The administration of a pressor dose of angiotensin II
resulted in a significant increase in mean arterial blood
pressure compared with all other groups (Figure 2a). No
significant differences in blood pressure were observed in the
other groups. The pressor dose of angiotensin II resulted in
higher plasma creatinine concentrations compared with all
other groups (Figure 2b). In addition, the aldosterone-treated
group also had higher plasma creatinine concentrations than
the control group. Both aldosterone and angiotensin II
reduced plasma potassium, but only aldosterone caused frank
hypokalemia (3.2±0.06mmol/l versus 4.3–5.2mmol/l in the
other groups, Po0.05 for all). Treatment with aldosterone
and angiotensin II resulted in significantly lower 6-day
cumulative sodium excretions compared with control
(21±3mmol for Aldo, 31±3mmol for angiotensin II in a
non-pressor, and 26±7mmol for angiotensin II in a pressor
versus 39±2mmol for control; Figure 2c). In addition, the
animals treated with aldosterone had a lower cumulative
sodium excretion than the animals treated with the non-
pressor dose of angiotensin II. A separate study showed that
the sodium retention caused by angiotensin II could be
inhibited by hydrochlorothiazide (Figure 2d).
Differential centrifugation and analysis by immunoblotting
The abundance of both transport proteins and regulatory
proteins was analyzed by immunoblotting. As transport
proteins are predominantly localized in plasma membrane,
and regulatory proteins in the intracellular compartment,
we used differential centrifugation to enrich both fractions
(see Materials and Methods). A confirmation of this method
is shown in Supplementary Figure S1 online, illustrating
the enrichment of proteins localized in the plasma membrane
(P-cadherin, sodium hydrogen exchanger type 3) or intra-
cellular compartment (WNK4). Of all proteins tested and
reported below, at least three immunoblots were performed.
All results were consistent and showed similar statistics; the
most representative immunoblots are shown. A Coomassie
loading gel confirmed equal loading among the groups with a
variation of o10% (Supplementary Figure S2 online).
Angiotensin II and aldosterone independently increased NCC,
ENaC, and aquaporin-2
In these adrenalectomized rats, the non-pressor and pressor
dose of angiotensin II increased the plasma membrane
abundance of NCC 4.5- and 3.5-fold (Figure 3). Aldosterone
increased the plasma membrane abundance of NCC threefold.
The plasma membrane abundance of NCC did not differ
between the three experimental groups. Interestingly, both
aldosterone and angiotensin II increased the plasma membrane
abundance of aquaporin-2 three- to fivefold compared with
controls. This effect was stronger and dose-dependent in the
angiotensin II-treated groups (higher abundance of aquaporin-
2 with angiotensin II in a non-pressor versus Aldo and with
angiotensin II in a pressor versus angiotensin II in a non-
pressor). Only the non-pressor dose of angiotensin II selectively
increased the plasma membrane abundance of the b-subunit of
ENaC 1.8-fold. Conversely, only aldosterone treatment selec-
tively increased the plasma membrane abundance of the
a-subunit of ENaC approximately twofold. The infusion of
angiotensin II or aldosterone did not result in significant
differences in the plasma membrane abundance of the sodium
hydrogen exchange type 3 and the sodium potassium chloride
cotransporter type 2.
Angiotensin II increased SPAK independent of aldosterone
The non-pressor dose of angiotensin II significantly increased
the intracellular abundance of SPAK twofold compared with
the control group (Figure 4). This effect was not observed
with the pressor dose of angiotensin II, which caused a lower
intracellular abundance of SPAK than the non-pressor dose.
Aldosterone treatment also increased the intracellular abun-
dance of SPAK approximately threefold, which was signifi-
cantly higher than the intracellular abundance of SPAK in all
other groups. Aldosterone increased the phosphorylation of
Table 1 | Experimental design
Control Aldosterone Angiotensin II non-pressor Angiotensin II pressor
No. of animals 5 5 5 5
Adrenalectomy Yes Yes Yes Yes
Infusion No Aldosterone (50mg/kg/day) Angiotensin II (233 mg/kg/day) Angiotensin II (700 mg/kg/day)
Dexamethasone (12mg/kg/day) Yes Yes Yes Yes
Drinking fluid 0.9% NaCl 0.9% NaCl 0.9% NaCl 0.9% NaCl
Hormones presenta Angiotensin II Angiotensin II Aldosterone + Angiotensin II + Angiotensin II ++
a‘+’ Indicates high physiological concentration, ‘++’ indicates supra-physiological concentration.
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SPAK at serine-373 6.1-fold compared with control. The
pressor dose of angiotensin II modestly reduced the
intracellular abundance of SGK1 compared with the control
group and with the group receiving aldosterone (both
approximately 1.4-fold). The intracellular abundance of
the other regulatory proteins that were tested, including
OSR1, phosphorylated OSR1, WNK4, and NEDD4-2, did not
change significantly.
Phosphorylation of NCC by angiotensin II and aldosterone
We analyzed whether angiotensin II also stimulated the
phosphorylation of NCC. Indeed, the non-pressor dose of
angiotensin II increased phosphorylation of NCC at threo-
nine-53 in plasma membrane 4.3-fold (Figure 5). Aldoster-
one also increased the phosphorylation of NCC at threonine-
53 and to the same degree as the non-pressor dose of
angiotensin II. Only aldosterone significantly increased
phosphorylation of NCC at threonine-58 (1.7-fold). An
antibody that recognized phosphorylation at both threonine-
53 and threonine-58 also showed increased phosphorylation
of NCC in the plasma membrane by aldosterone and by the
non-pressor dose of angiotensin II.
Immunohistochemistry of phosphorylated NCC and
aquaporin-2
Figure 6 shows immunohistochemistry for phosphorylated
NCC at threonine-53 and for aquaporin-2. Immunohisto-
chemistry showed increased labelling of phosphorylated NCC
and aquaporin-2 in the three experimental groups, thereby
confirming the immunoblotting results. In addition, Figure
6b shows that aquaporin-2 labelling was predominantly
increased in the basolateral membrane.
DISCUSSION
In the present study, our aim was to test the hypothesis that
angiotensin II regulates the NCC independently of aldoster-
one. Indeed, this is the first controlled in vivo study to show
that angiotensin II under a chronic setting increased the
abundance and phosphorylation of NCC independently of
aldosterone, leading to sodium retention. The observation
that sodium retention, secondary to angiotensin II, could be
inhibited by thiazides (Figure 2d) suggests that at least part of
this effect was mediated via NCC. However, it is not a direct
proof of an NCC-mediated effect, because we did not test
whether angiotensin II-treated animals were more sensitive
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Figure 1 |Activity or concentrations of components of the renin–angiotensin–aldosterone system. Plasma renin activity (a), and
plasma concentrations of angiotensin I (b), angiotensin II (c), and aldosterone (d). Plasma angiotensin II was expressed as natural logarithm
because of a nonlinear distribution. Groups were compared by analysis of variance (ANOVA) followed by a post-hoc test (see Materials and
Methods). A second control group (C-sham) was included as a normal reference (rats that were sham-operated only, no infusion of
hormones).
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to thiazides than control animals; it also remains to be
determined whether the effect was direct. Because SPAK has
been identified as a protein capable of phosphorylating the
N-terminal regulatory regions of NCC,12 the observed
increase in SPAK (Figure 4) suggests its involvement in the
phosphorylation of NCC (Figure 5). Although observational,
our results provide further insight in the current model of
the regulation of NCC (Figure 7). Namely, our data confirm
previous suggestions that two separate signaling pathways
regulate NCC, one originating from the angiotensin II type 1
receptor and one originating from the mineralocorticoid
receptor (Figure 7). The net effect of both signaling pathways
is a stimulation of sodium chloride reabsorption by NCC
in the distal convoluted tubule. Although trafficking and
phosphorylation of NCC by angiotensin II has been shown
previously,18,19 this is the first study to demonstrate that these
processes can occur independently of aldosterone.
Recently, in vitro studies have identified SPAK, WNK4,
and SGK1 as important regulatory kinases in the signaling
pathways stimulated by angiotensin II and aldosterone.8,11,13
For example, San-Cristobal et al.13 showed in oocytes of
Xenopus and mpkDCT cells that the regulation of NCC
by angiotensin II depends on both SPAK and WNK4.
Furthermore, Rozansky et al.11 showed in oocytes of Xenopus
and HEK293 cells that aldosterone mediates the activation
of NCC through SGK1-induced phosphorylation of the
C-terminal WNK4. These findings prompted us to also
analyze these NCC regulatory proteins.
We showed that both angiotensin II and aldosterone
increased the intracellular abundance of SPAK, but not OSR1
(Figure 4). The explanation for the fact that the intracellular
abundance of SPAK was increased significantly more in
the aldosterone-treated rats may be the consequence of the
well-known synergistic interaction between (exogenous)
aldosterone and (endogenous) angiotensin II in this group
(Figure 1).20 The phosphorylation of SPAK also increased
with angiotensin II and aldosterone, but this change was
significant only for the latter. Recently, Chiga et al.12 used
low- and high-sodium diets in mice to analyze the effects of
high and low aldosterone levels (plasma aldosterone B800
andB100 pg/ml) on SPAK, OSR1, and their phosphorylated
forms. A high plasma aldosterone concentration increased
the phosphorylation of SPAK and OSR1, but not their
abundances.12 Although our study confirms that aldosterone
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Figure 2 |Blood pressure, renal function, plasma potassium, and cumulative urine sodium excretion. Blood pressure (a), plasma
creatinine (b), 6-day cumulative urine sodium excretion (c), and the effects of thiazides on 6-day cumulative urine sodium excretion (d).
Cumulative sodium excretion was calculated based on 6-day urine volume and urine sodium (days 1 and 2 were discarded). Blood pressure
was analyzed by a repeated measures general linear model. All other analyses were performed by analysis of variance followed by a
post-hoc test (see Materials and Methods).
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increases the phosphorylation of SPAK, we also observed an
increase in the intracellular abundance of SPAK, but saw no
effect on phosphorylated OSR1 (Figure 4). These differences
may be related to the experimental models (diet versus
infusion), species (mice versus rats), or tissue preparation
(whole kidney homogenates versus intracellular fractions).12
Despite our confirmation of the importance of SPAK,
we observed no change in the intracellular abundance of
WNK4 with angiotensin II or aldosterone (Figure 4). This is
in agreement with two recent studies which also demon-
strated the unchanged WNK4 abundance with low-sodium
diet (high aldosterone)12 and with chronic angiotensin II
infusion.21 However, these results do not preclude a role for
WNK4, because it may be regulated through phosphorylation
rather than through abundance, as shown by Rozansky
et al.11 Because we analyzed whole kidney homogenates, an
alternative explanation is an opposite effect on WNK4
abundance in another nephron segment expressing WNK4
(e.g., thick ascending limb or collecting duct).
Similar to WNK4, we observed no change in SGK1 with
aldosterone or the non-pressor dose of angiotensin II, and
even observed a modest reduction in SGK1 with the pressor
dose of angiotensin II (Figure 4). Especially, the lack of
response in SGK1 with aldosterone is surprising, because
Vallon et al.22 recently showed that increased abundance and
phosphorylation of NCC with low-sodium diet (high
aldosterone) did not occur in SGK1 knockout mice,
illustrating the central role of SGK1 in NCC regulation. It
has been proposed that angiotensin II also mediates its effect
on the NCC via SGK1,15,23 but this has not been confirmed
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Figure 3 | Immunoblots of renal sodium and water transporters. Immunoblots showing the plasma membrane abundance of renal
sodium and water transport proteins. These include the sodium hydrogen exchange type 3 (NHE3), the sodium potassium chloride
cotransporter type 2 (NKCC2), the sodium chloride cotransporter (NCC), the water channel aquaporin-2 (AQP2), and finally the a-, b-, and
g-subunits of the epithelial sodium channel (ENaC). Groups were compared by analysis of variance followed by a post-hoc test (see Materials
and Methods).
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experimentally. Although the pressor dose of angiotensin II
reduced SGK1 (Figure 4), we are reluctant to conclude that
this was primarily because of angiotensin II, as these animals
also had additional variables that could have caused this
effect (i.e., hypertension and higher plasma creatinine;
Figure 2). The same explanations for why WNK4 was
unchanged in our model may also apply to SGK1. In
addition, the effect of aldosterone on SGK1 may be dose
dependent. For example, Hou et al.24 demonstrated an
eightfold rise in SGK1 mRNA in normal mice, but their
plasma aldosterone concentrations were 410 times than in
our aldosterone-treated rats. Using in situ hybridization,
Chen et al.9 also showed an increased abundance of SGK1
in adrenalectomized rats receiving aldosterone, but they also
used 2 to 3 times higher dosing than we did. Finally,
the plasma aldosterone concentrations of the mice on a
low-sodium diet in the study by Vallon et al.22 were almost
twice as high as the ones in our aldosterone-treated rats.
A separate focus of this study was the effects of
angiotensin II and aldosterone on the water channel
aquaporin-2. Interestingly, both aldosterone and angiotensin
II increased the plasma membrane abundance of aquaporin-
2, showing the highest abundance with a pressor dose of
angiotensin II (Figure 3). The observed upregulation of
aquaporin-2 by angiotensin II may represent a direct effect25
or an indirect effect because of the ability of angiotensin II
to increase vasopressin release.26 Previously, the role of
angiotensin II in aquaporin-2 regulation has been demon-
strated in vivo in urinary tract obstruction.27,28 In
mpkCCDc14 cells, long-term incubation with aldosterone
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also increased aquaporin-2 protein abundance by increasing
aquaporin-2 mRNA translation.29 Our immunohistochem-
istry results (Figure 6) confirm that of De Seigneux et al.,30
who also showed that aldosterone increased the basolateral
staining of aquaporin-2 in the cortical collecting duct of
rats.30 They hypothesized that in situations of increased
sodium reabsorption, a higher permeability of the basolateral
membrane may facilitate water efflux to prevent cell swelling.
Except for aquaporin-2, the effects of the pressor dose of
angiotensin II tended to be less pronounced than the effects
of the non-pressor dose (Figure 3–5). Possible explanations
include the presence of hypertension (Figure 2a), reduced
renal function (Figure 2b), or a downregulation of the
angiotensin II type 1 receptor. As anticipated from previous
studies, aldosterone also increased NCC,3 in addition to
a-ENaC7 (Figure 4). Interestingly, the non-pressor dose of
angiotensin II selectively increased b-ENaC. Previously,
angiotensin II has been shown to increase the activity of
ENaC.31 However, the ENaC subunits appear differentially
regulated by angiotensin II, because an angiotensin receptor
blocker decreased a-ENaC, but increased b-ENaC.32 There-
fore, an alternative explanation could be that not angiotensin
II but vasopressin increased b-ENaC, which was shown
previously33 and would also be consistent with the observed
increase in aquaporin-2.
In this study, we focused on the regulation of NCC.
Although NCC reabsorbs only 5–10% of the filtered load of
sodium chloride,19 altered function of this cotransporter has
profound effects on total body sodium and blood pressure.
This is illustrated by the fact that thiazides, which inhibit NCC,
are among the most effective antihypertensive drugs.34
Similarly, monogenetic disorders that result in inactivation
(Gitelman’s syndrome) or overactivation (Gordon’s syndrome)
of NCC are also characterized by salt-loss and low-normal
blood pressure, or salt-retention and hypertension, respec-
tively.35 Finally, polymorphisms in genes encoding for NCC
regulatory proteins, including WNK kinases and SPAK, are
associated with variations in blood pressure in populations.36,37
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Unravelling the independent effects of angiotensin II and
aldosterone on NCC is important both physiologically
and pathophysiologically. Physiologically, because angiotensin
II and aldosterone had similar effects on sodium and water
transporters (Figure 3), both hormones appear to act in concert
to maintain extracellular fluid volume during hypovolemia
(when both hormones are elevated). Pathophysiologically, the
renin–angiotensin–aldosterone system is activated in many
disease states, and therefore, angiotensin II and aldosterone
appear to individually contribute to sodium retention, which
may result in edema and hypertension. These separate effects
are important when selecting appropriate pharmacological
intervention with angiotensin-converting enzyme inhibitors,
angiotensin receptor blockers, or mineralocorticoid receptor
blockers.
We believe that the strength of this study was the ability to
analyze the effects of angiotensin II independent of
aldosterone by performing adrenalectomy and then infusing
angiotensin II. Adrenalectomy resulted in virtually undetect-
able aldosterone levels in the angiotensin II-treated groups
(Figure 1), thus confirming the validity of this approach.
Other evidence supporting our animal model were aldoster-
one-induced hypokalemia and sodium retention, and
angiotensin II-induced sodium retention and hypertension
(Figure 2). Animals receiving aldosterone retained most of
the sodium, but did not develop hypertension. This suggests
that hypertension induced by the pressor dose of angiotensin
II was mainly because of other mechanisms such as
vasoconstriction, which may also explain the reduction in
renal function (Figures 1 and 2). A previous study also
showed reduced renal function with a pressor dose of
angiotensin II, which was attributed to renal cortical
vasoconstriction.38 The consequent decreased distal sodium
delivery may explain why more angiotensin II infusion did
not result in more sodium retention.
We acknowledge that our study has limitations. Most
importantly, because whole kidney homogenates were used,
some of the observed changes in protein abundance may not
be specific for one nephron segment. In addition, the fact
that plasma angiotensin II levels were not higher in animals
receiving angiotensin II (Figure 1c) implies that plasma
angiotensin II levels do not always correspond with their
pNCC Thr-53a
b Aquaporin-2
ADX+ANG II-NP
ADX ADX+aldo
ADX ADX+aldo
ADX+ANG II-NP ADX+ANG II-P
ADX+ANG II-P
Figure 6 | Immunohistochemistry for the phosphorylated
sodium chloride cotransporter (pNCC) and aquaporin-2.
Immunohistochemistry for (a) the pNCC threonine-53 (Thr-53) and
(b) the water channel aquaporin-2. a shows representative images
of rat distal tubule, b of rat collecting duct cells. In a and b,
the upper left panel shows the control group, which only
underwent adrenalectomy (ADX). The three experimental groups
also underwent adrenalectomy, and were also treated with
aldosterone (ADXþAldo, upper right), a non-pressor dose of
angiotensin II (ADXþANG II-NP, lower left), or a pressor dose of
angiotensin II (ADXþANG II-P, lower right). In a and b, the more
intense staining in the three experimental groups compared with
the control group is clearly visible. In b, aquaporin-2 staining is
especially intense in the basolateral membrane.
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Figure 7 |Model for the regulation of the sodium chloride
cotransporter (NCC) by increasing plasma membrane
abundance and phosphorylation. Effects are stimulatory (plus
signs) or inhibitory (minus signs). ‘P’ denotes phosphorylation.
The combined minus sign and phosphorylation sign next to with-
no-lysine kinase (WNK) 4 means that serum- and glucocorticoid-
inducible kinase 1 (SGK1) phosphorylates WNK4 and thereby
decreases its activity16 WNK3 was not analyzed in this study. The
role of WNK1 and kidney-specific WNK1 is not shown. The model
is in part based on the findings in this study and in part on
previous literature.13,16–18,20,43
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biological effect. We speculate that this may be explained by
differences between endogenous and exogenous angiotensin
II, accumulation of angiotensin II in renal tissue, or
differences in angiotensin II degrading enzymes.39 Finally,
we appreciate that phosphorylation is sometimes expressed as
the ratio between the phosphorylated and total amount of
protein.12 We chose not to do this, because it remains unclear
whether there is a linear relationship between phosphory-
lation and total protein abundance. In addition, the increase
in regulatory kinases suggested that more phosphorylation
took place.
In summary, in adrenalectomized rats, angiotensin II
increased the total and phosphorylated NCC independently
of aldosterone. Phosphorylation of NCC by angiotensin II
and aldosterone appears to be mediated through SPAK.
These results are important for understanding the molecular
physiology of sodium transport in the distal nephron, which
not only is essential for maintaining the extracellular fluid
volume, but also contributes to the pathophysiology of
several forms of hypertension.37,40,41
METHODS
Animal studies
The animal protocol was approved by the Animal Care Committee
of the Erasmus Medical Center (EUR 127-08-02). Male Sprague–-
Dawley rats (n¼ 20, 15 weeks old, average weight 300 grams) were
obtained from Charles River laboratories (Sulzfeld, Germany).
Animals were randomly assigned to one of the four groups (Table 1).
On day 0, all animals were anaesthetized under 3% isoflurane
inhalation and underwent adrenalectomy via a bilateral lumbodorsal
incision. Immediately after adrenalectomy (also day 0), all animals
received an osmotic minipump (model 2ml2 Alzet, Cupertino, CA,
USA) for 8 days to administer the hormones shown in Table 1.
All minipumps also contained dexamethasone (12 mg/kg/day, for
glucocorticoid replacement).42 After surgery, animals were placed in
metabolic cages (day–night cycle 12 h, temperature 23 1C) from day
0 until day 8. Normal rat chow and drinking fluid (0.9% NaCl) were
supplied ad libitum. Normal saline was selected to compensate for
natriuresis after adrenalectomy. Blood pressure was measured every
morning in conscious rats using a computerized tail cuff system
after a 7-day acclimatization period (Kent Scientific Corporation,
Torrington, CN, USA). On day 8, the animals were killed. A fifth
group of sham-operated rats was only used as a normal reference
for plasma renin activity, and plasma angiotensin I, II, and
aldosterone concentrations. In a separate animal study following
the same protocol, we compared urinary sodium excretion
in adrenalectomized rats which received an osmotic minipump
with vehicle, a non-pressor dose of angiotensin II (233 mg/kg/day),
or a non-pressor dose of angiotensin II plus hydrochlorothiazide
(18.75mg/kg/day).43
Tissue preparation and plasma measurements
Plasma renin activity, angiotensin I and II, and aldosterone were
measured using sensitive radioimmunoassays, as described pre-
viously.44,45 Plasma angiotensin II was expressed as natural
logarithm because of a nonlinear distribution. The detection limit
for plasma aldosterone was 1 pg/ml. If the measured value was below
the detection limit, a value of 1 pg/ml was used as dummy variable
for statistics. Immediately after the collection of blood, kidneys
were harvested and placed on ice. The right kidney was used for
immunoblotting and was placed in an isolation buffer (10mmol/l
triethanolamine, 250mmol/l sucrose, protease inhibitors (Complete
Roche Biochemicals, Roche Diagnostics, Almere, The Netherlands))
and homogenized. The whole kidney homogenate was subjected to
differential centrifugation to separate the plasma membrane from
the intracellular fraction, as described previously.46 The pellet
(plasma membrane fraction) was resuspended in 1ml isolation
buffer. A total of 60 ml of both fractions were used for quantitative
protein assay (Pierce, Thermo Scientific, Rockford, IL, USA) and
the remaining samples were stored in 6 Laemli at 80 1C for
immunoblotting.
Immunoblotting
Immunoblotting was performed as described previously.2 Samples
of all 20 rats were immunoblotted simultaneously using two gels in
one transfer apparatus including an internal standard. All
immunoblots were performed at least three times to confirm
linearity and reproducibility. Equal protein loading was confirmed
with Coomassie (Supplementary Figure S2 online). Antibodies
against the transport proteins, sodium hydrogen exchanger type 3
(1:5000), sodium potassium chloride cotransporter type 2
(1:10,000), NCC (1:500), the a-, b-, and g-subunits of ENaC
(1:100, 1:1000, 1:500), and aquaporin-2 (1:1000) were kindly
provided by Dr MA Knepper.47 Antibodies against phosphorylated
NCC at threonine-53 and/or -58 were generated by one of the
investigators (RAF, all 1:500).48 Antibodies against all other
proteins were obtained: SPAK (Cell Signaling Technology, Leiden,
The Netherlands, 1:300), SGK1 (Millipore, Billerica, MA, USA,
1:2000), and NEDD4-2 (Abcam, Cambridge, UK, 1:4000). Similarly,
WNK4 (1:500), OSR1 (1:1000), and an antibody that recognized
phosphorylated SPAK at serine-373 and phosphorylated OSR1 at
serine-325 (4mg/ml with 40ml of the non-phosphorylated peptide)
were obtained from the Division of Signal Transduction Therapy,
University of Dundee.8
Immunohistochemistry
The left kidney was used for immunohistochemistry. The midregion
was sectioned into 2- to 3-mm transverse sections and immersion-
fixed for an additional 1 h, followed by 3 10min washes with
0.1mol/l cacodylate buffer, pH 7.4. The tissue was dehydrated in
graded ethanol, incubated overnight in xylene, and embedded in
paraffin, and 2-mm sections were cut on a rotary microtome (Leica
Microsystems, Herlev, Denmark). Immunolabeling was performed
as described previously.27,48 Labeling was detected using a horse-
radish peroxidase-conjugated secondary antibody (Dako P448, goat
anti-rabbit IgG, Glostrup, Denmark) and visualized with 0.05%
3,30-diaminobenzidine tetrachloride (Kemen Tek, Copenhagen,
Denmark). Light microscopy was carried out with a Leica DMRE
(Leica Microsystems).
Statistics
All data are expressed as means and s.e. of the mean. Group
comparisons were made by analysis of variance using the least
significant difference as post-hoc test. Blood pressure data were
analyzed using repeated measures general linear model, which
generates one P-value for the overall difference over time between
the groups. Po0.05 was considered statistically significant.
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Figure S1. Coomassie loading gels for plasma membrane and
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